American chemical industry news (page 5)

• 

  31 March 2026

  BASF launches Butyl and 2‑Ethylhexyl Acrylate RE with Avery Dennison

  Launches butyl and 2‑ethylhexyl acrylates made using attributed Texas renewable electricity; drop‑in for coatings and adhesives, reducing manufacturing CO2; commercialization supported by partner.
• 

  31 March 2026

  Kemira completes first US full-scale trial of chlorine-free KemConnect DEX

  Trial with Capital Region Water shows a performic-acid, chlorine-free treatment cut bacteria rapidly at low doses, auto-degraded to biodegradable compounds and auto-adjusted dosing.
• 

  31 March 2026

  LanzaTech Q4 & FY2025 Financial Results

  Closed $20M private placement; awarded €40M EU grant; completed LanzaJet share transfers (peak 53%, later ~46% after Series A); revenue $55.8M; net loss $49M; opex -21%
• 

  31 March 2026

  PPG showcases electrocoat and digital innovations at ECOAT 26

  At ECOAT 26, new pretreatment and electrocoat technologies, digital paint‑shop tools and services to cut waste and costs, boost efficiency; exec keynote and interactive demo included.
• 

  31 March 2026

  Johnson Matthey DPFi DPF earns Canadian CSA certification

  Electrically regenerating diesel particulate filter certified by CSA for Canadian underground mining/tunnelling; also certified by Canmet and VERT and approved by US MSHA.
• 

  31 March 2026

  Lilly to acquire Centessa Pharmaceuticals for OX2R sleep‑wake portfolio

  $38/ADS cash + up to $9 CVR (max $47/sh); upfront equity ~$6.3B (CVR ~$1.5B). Lead OX2R agonist cleminorexton showed positive Phase 2a for narcolepsy and idiopathic hypersomnia. Close expected Q3

• 

  31 March 2026

  Messer 2025 results: €4.5bn revenue, €1.4bn EBITDA, €747m investments

  Stable 2025: margin held, net debt reduced, staff >12k. Investments in air-separation, on-site/CO2/cylinder plants, helium, decarbonization, R&D/digitalization. 2026 growth expected.
• 

  30 March 2026

  Golden Pass LNG (QatarEnergy/ExxonMobil) achieves first LNG production

  First LNG produced from Train 1 of the 18 mtpa Sabine Pass project, enabling sustained liquefaction and paving way for first cargo and full exports beginning Q2 2026.
• 

  30 March 2026

  Merck enlicitide decanoate, an oral PCSK9 inhibitor, reduces LDL‑C more than guideline non‑statins at 8 weeks

  Phase 3 CORALreef AddOn: enlicitide lowered LDL‑C 64.6% at 8 weeks; 78.2% achieved ≥50% reduction and LDL‑C <55 mg/dL; safety comparable to oral non‑statins; FDA CNPV awarded
• 

  30 March 2026

  Siemens USA appoints Ann Fairchild President & CEO

  Ann Fairchild, with 25+ years at the company, named permanent president & CEO of its U.S. unit; will oversee ~50,000 employees and $24B revenue, focusing on AI, infrastructure and reshoring.
• 

  30 March 2026

  Velocys and SuMo commission Fischer–Tropsch unit at Wednesbury for UK waste-to-SAF

  FT unit at Wednesbury is online and stable, validating integration of gasification and FT for waste-to-SAF and supporting ClearSkies demonstration toward modular, scalable SAF production.
• 

  30 March 2026

  GSK's bepirovirsen accepted for regulatory review in China for chronic hepatitis B

  China NMPA accepted NDA for bepirovirsen after Phase III B-Well trials showed significant functional cure rates in treated CHB patients; granted Breakthrough Therapy; acceptable safety.
• 

  30 March 2026

  GSK’s Exdensur approved in China for severe eosinophilic asthma

  First ultra-long-acting IL-5 biologic for eosinophilic severe asthma; twice-yearly dosing cut annual exacerbations by ~48–58% in SWIFT trials and lowered hospital/ED visits.
• 

  29 March 2026

  Merck: WINREVAIR Phase 2 CADENCE shows proof‑of‑concept in CpcPH‑HFpEF

  Met primary endpoint with significant PVR reduction at 24 weeks vs placebo. Also favorable mPAP/PAWP, NT‑proBNP and 6MWD trends, delayed clinical worsening; safety consistent with known profile.
• 

  28 March 2026

  Amgen: Repatha cuts first major cardiovascular events 31% in high‑risk patients without significant atherosclerosis

  VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.
• 

  28 March 2026

  Takeda’s Zasocitinib: Once‑daily pill achieves rapid, durable clearance in plaque psoriasis

  Phase 3: ~70% reached sPGA 0/1 at week 16; PASI90 up to 61%, PASI100 up to 33%. Responses rose through week 24 and >90% of responders maintained effect to week 60. Safety consistent with prior studies
• 

  28 March 2026

  Johnson & Johnson STEMI-DTU RCT: LV unloading with delayed reperfusion does not increase infarct size

  Neutral trial. 30‑min Impella improved pre‑PCI TIMI flow. Age 61+ trended smaller infarcts. More bleeding/vascular events but no higher 12‑month mortality. Elevated lactate predicted larger infarcts.
• 

  28 March 2026

  Johnson & Johnson: ICOTYDE (icotrokinra) 52‑week data show sustained skin clearance and favorable safety

  ICONIC Phase 3: PASI100 rose to 49%/48% (ADVANCE 1/2) by Week52; placebo switchers matched. Adolescents: 57% PASI100, 86% PASI90 at 52w. No new safety signals; fewer AEs vs deucravacitinib.
• 

  28 March 2026

  Lilly: Taltz + Zepbound superior to Taltz alone in psoriatic arthritis with obesity

  Phase 3b TOGETHER‑PsA: combination therapy improved ACR50, MDA, fatigue, function, QoL and cardiometabolic markers; 36‑week primary endpoint met (ACR50+≥10% weight loss 31.7% vs 0.8%).
• 

  27 March 2026

  Eastman raises ester prices effective April 1, 2026

  isobutyl acetate +$0.15/lb (NA, LatAm), +$0.28/lb (APAC); n-butyl (excl Eastapure) +$0.15/lb (NA, LatAm); n-propyl +$0.15/lb (NA, LatAm). Cited higher raw-material and energy costs.
• 

  27 March 2026

  Sasol — Middle East developments and business impact

  Middle East conflict disrupted gas supply - ORYX GTL shut; ~60 staff safe. Fuel and chemicals impacted; Secunda/Natref secure inventories and alternative crude; contingencies active.
• 

  27 March 2026

  Lilly's EBGLYSS: durable 4‑year control in moderate‑to‑severe atopic dermatitis

  Up to four years of monthly maintenance produced durable skin clearance (EASI‑75 94%, EASI‑90 75%, IGA 0/1 68%), itch relief (Pruritus NRS≤4: 78%), 80% without topical steroids; safety consistent.
• 

  27 March 2026

  Fondazione MAIRE presents Climate Goals study in Berlin

  Fourth edition of Climate Goals study shows Germany as highly aware, pragmatic on energy transition; emphasizes technical focus, workforce upskilling, and shift of momentum toward emerging economies.
• 

  27 March 2026

  GSK bepirovirsen accepted for EMA review for chronic hepatitis B

  EMA accepted bepirovirsen MAA for chronic hepatitis B after Phase III B‑Well 1/2 showed higher functional cure rates vs standard of care; safety profile acceptable.
• 

  27 March 2026

  Avangrid completes 250,000-panel Tower Solar installation in Oregon

  120 MWac plant due online this year; panels built by SEG Solar in Houston. Will feed PGE grid and support a QTS data center; construction created 200+ local jobs and ~$20M economic benefit.
• 

  26 March 2026

  Toray Industries imposes emergency surcharges after crude and naphtha price surge

  Temporary surcharges on petrochemical products after crude/naphtha price spike from Middle East tensions and Hormuz blockade; reviewed regularly to secure supply.
• 

  26 March 2026

  FDA approves Novo Nordisk Awiqli, first once-weekly basal insulin for adults with type 2 diabetes

  ONWARDS trials (~2,680 pts) showed A1C reductions vs daily basal; safety aligned with class. Key risks: hypoglycemia, injection-site reactions, weight gain. US launch pending
• 

  26 March 2026

  Novo Nordisk gains US approval for Awiqli, first once‑weekly basal insulin for adults with type 2 diabetes

  ONWARDS phase‑3 (~2,680 adults) showed HbA1c reductions vs daily basal insulin with similar safety. US launch planned H2 2026; also approved in EU and 13 other countries.
• 

  26 March 2026

  BASF Coatings appoints Jens Luehring CEO after Carlyle deal closes

  Dr Uta Holzenkamp will lead until closing and then support the transition. Deal needs customary approvals; close expected Q2 2026. Incoming CEO has extensive carve-out and M&A experience.
• 

  26 March 2026

  Topsoe terminates supply agreements with First Ammonia

  Partner missed key milestones despite extensions, triggering automatic termination. Company still has a 50 MW offtake in place and will complete an SOEC commercialization roadmap by end Q2 2026.